CpG DNA in the Prevention and Treatment of Infections

ISSN： 1173-8804

Source： BioDrugs, Vol.16, Iss.6, 2002-01, pp. : 419-431

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The CpG Motif: Implications for Clinical Immunology

By Krieg A.M.

BioDrugs, Vol. 10, Iss. 5, 1998-11 ,pp. : 341-346

Adis International

Access to resources Recommend Favorite

CpG Oligodeoxynucleotides as TLR9 Agonists: Therapeutic Application in Allergy and Asthma

By Gupta Gaurav K. Agrawal Devendra K.

BioDrugs, Vol. 24, Iss. 4, 2010-08 ,pp. : 225-235

Adis International

Access to resources Recommend Favorite

CpG Oligodeoxynucleotides as TLR9 Agonists: Therapeutic Applications in Cancer

By Murad Yanal M. Clay Timothy M.

BioDrugs, Vol. 23, Iss. 6, 2009-12 ,pp. : 361-375

Adis International

Access to resources Recommend Favorite

Therapeutic Applications of Synthetic CpG Oligodeoxynucleotides as TLR9 Agonists for Immune Modulation

By Jurk Marion Vollmer Jörg

BioDrugs, Vol. 21, Iss. 6, 2007-01 ,pp. : 387-401

Adis International

Access to resources Recommend Favorite

Bacteriophages: Potential Treatment for Bacterial Infections

By Duckworth D.H. Gulig P.A.

BioDrugs, Vol. 16, Iss. 1, 2002-01 ,pp. : 57-62

Adis International

Access to resources Recommend Favorite